57 related articles for article (PubMed ID: 12879008)
1. The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.
Miething C; Grundler R; Fend F; Hoepfl J; Mugler C; von Schilling C; Morris SW; Peschel C; Duyster J
Oncogene; 2003 Jul; 22(30):4642-7. PubMed ID: 12879008
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice.
Lange K; Uckert W; Blankenstein T; Nadrowitz R; Bittner C; Renauld JC; van Snick J; Feller AC; Merz H
Oncogene; 2003 Jan; 22(4):517-27. PubMed ID: 12555065
[TBL] [Abstract][Full Text] [Related]
3. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas.
Jäger R; Hahne J; Jacob A; Egert A; Schenkel J; Wernert N; Schorle H; Wellmann A
Anticancer Res; 2005; 25(5):3191-6. PubMed ID: 16101126
[TBL] [Abstract][Full Text] [Related]
4. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
[TBL] [Abstract][Full Text] [Related]
5. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
6. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
Turner SD; Tooze R; Maclennan K; Alexander DR
Oncogene; 2003 Oct; 22(49):7750-61. PubMed ID: 14586401
[TBL] [Abstract][Full Text] [Related]
7. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
Kuefer MU; Look AT; Pulford K; Behm FG; Pattengale PK; Mason DY; Morris SW
Blood; 1997 Oct; 90(8):2901-10. PubMed ID: 9376569
[TBL] [Abstract][Full Text] [Related]
9. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
Hsu FY; Zhao Y; Anderson WF; Johnston PB
Cancer Invest; 2007 Jun; 25(4):240-8. PubMed ID: 17612934
[TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
[TBL] [Abstract][Full Text] [Related]
12. CD2 promoter regulated nucleophosmin-anaplastic lymphoma kinase in transgenic mice causes B lymphoid malignancy.
Turner SD; Merz H; Yeung D; Alexander DR
Anticancer Res; 2006; 26(5A):3275-9. PubMed ID: 17094440
[TBL] [Abstract][Full Text] [Related]
13. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
14. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T
Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
[TBL] [Abstract][Full Text] [Related]
16. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
[TBL] [Abstract][Full Text] [Related]
17. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
Turner SD; Alexander DR
Leukemia; 2005 Jul; 19(7):1128-34. PubMed ID: 15902287
[TBL] [Abstract][Full Text] [Related]
18. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
[TBL] [Abstract][Full Text] [Related]
19. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
Kalinova M; Krskova L; Brizova H; Kabickova E; Kepak T; Kodet R
Leuk Res; 2008 Jan; 32(1):25-32. PubMed ID: 17320171
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
